---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-033797"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2025-04-10T23:59:59+00:00"
generated_at: "2026-05-23T17:25:16.421743+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics Announces Additional Preclinical Data and Phase 1b Study Design for GT-02287 in Parkinson's Disease

## Summary
- GT-02287 showed disease-modifying potential in GBA1 and idiopathic Parkinson's disease models, with biomarkers statistically reduced and lasting after drug washout.
- Phase 1b study ongoing; early biomarker analysis of enrolled participants expected mid-2025, including GBA1 mutation carriers and non-carriers.
- Complete Phase 1b endpoint analysis after 90 days of treatment anticipated in Q4 2025, guiding Phase 2 design in H2 2025.
- Oral presentation at AD/PD 2025 highlighted behavioral and biomarker data supporting GT-02287's disease-modifying capacity.

## SEC filing metadata
- accession: 0001104659-25-033797
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2025-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465925033797/0001104659-25-033797-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465925033797/tm2512000d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-033797
- JSON: https://secwatch.observer/filing/0001104659-25-033797.json
- Plain text: https://secwatch.observer/filing/0001104659-25-033797.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.